224 related articles for article (PubMed ID: 25304679)
21. [Successful desensitization protocol for patients with hypersensitivity reactions caused by carboplatin].
Nishio S; Koyanagi T; Miyabe K; Kuromatsu H
Gan To Kagaku Ryoho; 2010 Apr; 37(4):731-3. PubMed ID: 20414037
[TBL] [Abstract][Full Text] [Related]
22. A new rapid desensitization protocol for chemotherapy agents.
Gastaminza G; de la Borbolla JM; Goikoetxea MJ; Escudero R; Antón J; Espinós J; Lacasa C; Fernández-Benítez M; Sanz ML; Ferrer M
J Investig Allergol Clin Immunol; 2011; 21(2):108-12. PubMed ID: 21462800
[TBL] [Abstract][Full Text] [Related]
23. [Successful desensitization using cisplatin after carboplatin-associated hypersensitivity reactions in 3 cases with recurrent ovarian carcinoma].
Hosaka M; Ebina Y; Moriwaki M; Hara Y; Araki N; Todo Y; Takeda M; Watari H; Sakuragi N
Gan To Kagaku Ryoho; 2007 Sep; 34(9):1505-8. PubMed ID: 17876157
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of intraperitoneal carboplatin with intravenous paclitaxel in patients with suboptimal residual epithelial ovarian or primary peritoneal cancer: a Sankai Gynecology Cancer Study Group Study.
Fujiwara K; Nagao S; Kigawa J; Noma J; Akamatsu N; Miyagi Y; Numa F; Okada M; Aotani E
Int J Gynecol Cancer; 2009 Jul; 19(5):834-7. PubMed ID: 19574769
[TBL] [Abstract][Full Text] [Related]
25. Desensitizing oxaliplatin-induced fever: a case report.
Madrigal-Burgaleta R; Berges-Gimeno MP; Angel-Pereira D; Guillen-Ponce C; Sanz ML; Alvarez-Cuesta E
J Investig Allergol Clin Immunol; 2013; 23(6):435-6. PubMed ID: 24459821
[No Abstract] [Full Text] [Related]
26. Hypersensitivity Reactions to Oxaliplatin: Identifying the Risk Factors and Judging the Efficacy of a Desensitization Protocol.
Okayama T; Ishikawa T; Sugatani K; Yoshida N; Kokura S; Matsuda K; Tsukamoto S; Ihara N; Kuriu Y; Nakanishi M; Nakamura T; Kamada K; Katada K; Uchiyama K; Takagi T; Handa O; Konishi H; Yagi N; Naito Y; Otsuji E; Hosoi H; Miki T; Itoh Y
Clin Ther; 2015 Jun; 37(6):1259-69. PubMed ID: 25862137
[TBL] [Abstract][Full Text] [Related]
27. Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management.
Hesterberg PE; Banerji A; Oren E; Penson RT; Krasner CN; Seiden MV; Wong JT
J Allergy Clin Immunol; 2009 Jun; 123(6):1262-7.e1. PubMed ID: 19501233
[TBL] [Abstract][Full Text] [Related]
28. High Efficacy and Low Toxicity of the Modified Docetaxel and Carboplatin Protocol in Patients with Recurrent Ovarian Cancer-A Phase 2 Cohort Study.
Bruchim I; Weeg N; Alpert Y; Sade D; Piura E; Fishman A
Int J Gynecol Cancer; 2016 May; 26(4):640-7. PubMed ID: 27101523
[TBL] [Abstract][Full Text] [Related]
29. Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions.
Markman M; Hsieh F; Zanotti K; Webster K; Peterson G; Kulp B; Spicel A; Belinson J
J Cancer Res Clin Oncol; 2004 Jan; 130(1):25-8. PubMed ID: 14564516
[TBL] [Abstract][Full Text] [Related]
30. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases.
Castells MC; Tennant NM; Sloane DE; Hsu FI; Barrett NA; Hong DI; Laidlaw TM; Legere HJ; Nallamshetty SN; Palis RI; Rao JJ; Berlin ST; Campos SM; Matulonis UA
J Allergy Clin Immunol; 2008 Sep; 122(3):574-80. PubMed ID: 18502492
[TBL] [Abstract][Full Text] [Related]
31. Oxaliplatin hypersensitivity complicated by thrombocytopenia during desensitization.
Tuttle KL; Stavrou E; Hong DIC; Connell NT; Wickner P
Ann Allergy Asthma Immunol; 2021 Aug; 127(2):267-269. PubMed ID: 33971363
[No Abstract] [Full Text] [Related]
32. Incidence of Carboplatin-related hypersensitivity reactions in Japanese patients with gynecologic malignancies.
Koshiba H; Hosokawa K; Kubo A; Miyagi Y; Oda T; Miyagi Y; Watanabe A; Honjo H
Int J Gynecol Cancer; 2009 Apr; 19(3):460-5. PubMed ID: 19407575
[TBL] [Abstract][Full Text] [Related]
33. A new non-dilution rapid desensitization protocol successfully applied to all-grade platinum hypersensitivity.
Chung SJ; Kang SY; Kang RY; Kim YC; Lee KH; Kim TY; Han SW; Kang HR
Cancer Chemother Pharmacol; 2018 Nov; 82(5):777-785. PubMed ID: 30105458
[TBL] [Abstract][Full Text] [Related]
34. Replacement of carboplatin by oxaliplatin may be one solution for patients treated for ovarian carcinoma who are hypersensitive to carboplatin.
Gutierrez M; Pautier P; Lhommé C
J Clin Oncol; 2002 Jan; 20(1):353. PubMed ID: 11773195
[No Abstract] [Full Text] [Related]
35. Complete metabolic response after carboplatin desensitization in Peritoneal Carcinomatosis.
Villarreal-González RV; González-Díaz SN; Vidal-Gutiérrez O; Zayas-Villanueva OA; Solís-Lara H; Santos-Fernández WJ; Casas-Murillo CA; López-Méndez A
J Oncol Pharm Pract; 2022 Sep; 28(6):1441-1445. PubMed ID: 35119322
[TBL] [Abstract][Full Text] [Related]
36. Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol.
Syrigou EI; Karapanagiotou EM; Alamara CV; Boura PG; Saif MW; Syrigos KN
Clin Colorectal Cancer; 2009 Apr; 8(2):106-9. PubMed ID: 19739272
[TBL] [Abstract][Full Text] [Related]
37. Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
Del Carmen MG; Supko JG; Horick NK; Rauh-Hain JA; Clark RM; Campos SM; Krasner CN; Atkinson T; Birrer MJ
Cancer; 2016 Nov; 122(21):3297-3306. PubMed ID: 27421044
[TBL] [Abstract][Full Text] [Related]
38. Successful carboplatin desensitization by using omalizumab and paradoxical diminution of total IgE levels.
Ojaimi S; Harnett PR; Fulcher DA
J Allergy Clin Immunol Pract; 2014; 2(1):105-6. PubMed ID: 24565780
[No Abstract] [Full Text] [Related]
39. Carboplatin hypersensitivity: evaluation and successful desensitization protocol.
Bruchim I; Goldberg A; Fishman A; Confino-Cohen R
Immunotherapy; 2014; 6(8):905-12. PubMed ID: 25313569
[TBL] [Abstract][Full Text] [Related]
40. Carboplatin desensitization - simplified 4-step 2-bag method.
Kintzel PE; Gressel GM; Van Rossum BT; Hillaker KN; Ice LL; Eastman JJ
J Oncol Pharm Pract; 2024 Jun; 30(4):759-766. PubMed ID: 38470451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
